TLSI TriSalus Life Sciences Inc: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

The linear price action on this chart demonstrates an EPS of 76.50. TriSalus Life Sciences (TLSI) develops exclusive drug delivery methods for the gastrointestinal tract, bypassing market competition through its patent portfolio. The business relies on partnerships with clinics to synthesize immunotherapy and drug delivery systems. Success depends on test accuracy, specialist approval, and the quality of equipment used in tumor treatment.
TriSalus Life Sciences - פילוחים אנליטיים ומדדי מפתח (TLSI)

Year-over-year (YoY) EPS growth (TTM) measures the annual change in trailing twelve-month net income per share, reflecting the efficiency of shareholder value generation. The current trajectory of EPS YoY TTM allows for the real-time assessment of deviations between actual returns and forecast expectations. The metric's dynamics depend critically on quarterly reporting, eliminating temporal gaps in the analysis. For TriSalus Life Sciences (TLSI), this indicator confirms the financial return from maximizing the utilization of production capacities for medical system assembly.